Company details

About

Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications

icon

Number of employees

1 - 10

icon

Main industry

Biotechnology

icon

Industry tags

icon

Founded in

2017

icon

Headquarters

New York

icon

Country

United States

Sign up to uncover company details

5 free credit every month

Employee contacts

Name

Job Title

Email

Phone

Reach Decision Makers
at Artara Therapeutics

5 Free credits every month!

Sign up now to uncover all the contact details